Biosim

About Biosim

BiosimAI operates at the intersection of biophysics and artificial intelligence, developing simulation methods for drug discovery. Founded in 2020 by Garegin Papoian, an expert in Theoretical and Computational Chemistry and Biophysics, the company is based in the Boston area. Papoian, who serves as the company's CSO, launched BiosimAI to apply his experience in developing new computational chemistry tools to the challenges of drug discovery. He identified that a startup environment could provide new opportunities for software development applicable to health and longevity that would be difficult to achieve in an academic setting.

In January 2024, BiosimAI merged with Deep Origin, a tech-for-bio startup founded by Michael Antonov, a co-founder of Oculus VR. Antonov's journey from virtual reality to life sciences was driven by an interest in longevity and the potential for software to unravel the complex interactions of genes and proteins. The merger integrated BiosimAI's physics-based modeling and AI with Deep Origin's infrastructure and scientific insights, creating a unified entity aimed at accelerating drug discovery. The combined company, operating as Deep Origin, believes that a hybrid approach, using both physics-based modeling and generative AI, is the most effective strategy for predicting which molecules can become viable drugs.

The company's core business is to significantly shorten the timeline for small-molecule drug discovery from years to months. It develops medical technology that leverages artificial intelligence to speed up the process, with a focus on discovering drugs for diseases previously considered undruggable. By combining physics-based modeling with AI, BiosimAI aims to create simulation methods that span from the atomic to the cellular scale. This technology helps pharmaceutical and biotech clients to reduce risks, increase the speed, and improve the success rate of their R&D activities. Prior to its merger, BiosimAI had raised $250K in funding.

The merger with Deep Origin provides BiosimAI's technology with access to a broader infrastructure, enabling scientists to bridge the gap from biological discoveries to drug candidates more rapidly and cost-effectively. Deep Origin specializes in handling the operational and engineering challenges in life sciences R&D, allowing researchers to concentrate on scientific innovation. The joint vision is to harness advanced genetic insights and simulated biological models to transform the therapeutic development process.